What's Going On With US Pharma Giant Bristol-Myers Squibb Stock Today?

Zinger Key Points
  • Bristol Myers Squibb forecasts fiscal year 2024 adjusted EPS of $7.10-$7.40 versus consensus of $7.08.
  • Total 2024 revenues are expected to increase by low-single-digits.

Bristol-Myers Squibb Company BMY said that its fourth-quarter revenues were $11.48 billion, up 1% Y/Y, beating the consensus of $11.19 billion, primarily due to higher sales of new product portfolio, as well as Eliquis and Opdivo, partially offset by lower sales of Revlimid.

U.S. revenues increased by 1% to $8.0 billion primarily due to higher sales of the new product portfolio, Eliquis and Opdivo, partially offset by lower sales of Revlimid.

Also Read: Focus On Bristol Myers, Gilead Sciences, Johnson & Johnson, Novartis: FDA To Issue Classwide Black Box Warning on CAR-T Therapies For Blood Cancer Treatment.

Sales of Eliquis were $2.87 billion, up 7% from last year. Sales of Revlimid fell 36% to $1.45 billion in the quarter. Sales of its cancer immunotherapy Opdivo rose 8% to $2.39 billion.

The company’s adjusted EPS was $1.70, down 7% Y/Y, beating the consensus of $1.53.

Guidance: Bristol-Myers Squibb forecasts fiscal year 2024 adjusted EPS of $7.10-$7.40 versus consensus of $7.00.

Total 2024 revenues are expected to increase by low-single-digits; Excluding foreign exchange, total revenues are expected to increase by low single-digits.

Read Next: Medicare’s Historic Negotiations To Lower Drug Prices, Analysts Anticipate Upto Potential Price Cuts Of 60%.

In January, BofA Securities downgraded Bristol-Myers Squibb, noting that initially, the analyst believed that Bristol’s loss of exclusivity for drugs like Eliquis and Opdivo was widely understood, and it was anticipated that a new product lineup would compensate for these losses and boost market value

Price Action: BMY shares are down 0.60% at $48.38 on the last check Friday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsEquitiesLarge CapNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!